Motus GI (NASDAQ:MOTS) versus Nemaura Medical (NASDAQ:NMRD) Head-To-Head Survey

Profitability

This table compares Motus GI and Nemaura Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Motus GI	N/A	N/A	N/A
Nemaura Medical	N/A	N/A	N/A

Insider and Institutional Ownership

20.1% of Motus GI shares are held by institutional investors. Comparatively, 4.4% of Nemaura Medical shares are held by institutional investors. 0.3% of Motus GI shares are held by company insiders. Comparatively, 40.4% of Nemaura Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Motus GI and Nemaura Medical”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Motus GI	$320,000.00	0.00	-$12.87 million	($15.64)	0.00
Nemaura Medical	$80,000.00	0.00	-$14.14 million	($0.39)	N/A

Motus GI has higher revenue and earnings than Nemaura Medical. Motus GI is trading at a lower price-to-earnings ratio than Nemaura Medical, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Motus GI has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Nemaura Medical has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500.

Summary

Motus GI beats Nemaura Medical on 4 of the 6 factors compared between the two stocks.

About Motus GI

Motus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.